Hudson Value Partners LLC Cuts Stock Holdings in Danaher Co. (NYSE:DHR)

Hudson Value Partners LLC lowered its holdings in shares of Danaher Co. (NYSE:DHR) by 3.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,695 shares of the conglomerate’s stock after selling 782 shares during the quarter. Danaher accounts for about 1.9% of Hudson Value Partners LLC’s portfolio, making the stock its 18th largest position. Hudson Value Partners LLC’s holdings in Danaher were worth $5,210,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. FMR LLC lifted its holdings in Danaher by 15.8% during the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after buying an additional 3,217,631 shares in the last quarter. Van ECK Associates Corp lifted its holdings in Danaher by 6,862.7% during the 4th quarter. Van ECK Associates Corp now owns 929,868 shares of the conglomerate’s stock valued at $213,452,000 after buying an additional 916,513 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after purchasing an additional 535,254 shares during the period. International Assets Investment Management LLC increased its position in Danaher by 40,196.5% during the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after purchasing an additional 428,897 shares during the period. Finally, Montrusco Bolton Investments Inc. increased its position in Danaher by 30.4% during the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after purchasing an additional 397,671 shares during the period. Institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. The trade was a 21.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.90% of the company’s stock.

Danaher Stock Down 1.0 %

Shares of Danaher stock opened at $204.22 on Wednesday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 52-week low of $196.80 and a 52-week high of $281.70. The company has a 50 day moving average of $228.34 and a 200 day moving average of $248.10. The company has a market capitalization of $147.50 billion, a P/E ratio of 38.68, a P/E/G ratio of 2.63 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the previous year, the business posted $2.09 EPS. As a group, research analysts forecast that Danaher Co. will post 7.67 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were given a dividend of $0.27 per share. The ex-dividend date was Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.53%. Danaher’s payout ratio is currently 20.45%.

Analyst Ratings Changes

DHR has been the topic of a number of research reports. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a research report on Friday, December 13th. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a research report on Thursday, October 31st. Stifel Nicolaus lifted their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research note on Wednesday, October 23rd. Finally, Scotiabank began coverage on shares of Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.